BackInsmed Overview
Insmed Inc

Insmed Target Price

Analysts' average 12-month price target for Insmed is $190.

Get informed when a big investor buys or sells

+ Follow

Share Price

$128.8

Average Target Price

$191.4648.7% upside

13 analysts in the last 4 months

High: $235 | Low: $161

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-10Truist Financial$19551.4% upsideOpen
2026-08-07Morgan Stanley$21869.3% upsideOpen
2026-08-07Evercore ISI$17032% upsideOpen
2026-08-07Guggenheim$20559.2% upsideOpen
2026-08-07UBS$17233.5% upsideOpen
2026-08-07Wells Fargo$16931.2% upsideOpen
2026-08-06Jefferies$17535.9% upsideOpen
2026-07-28Cantor FitzgeraldOlivia Brayer$23582.5% upsideOpen
2026-07-20BMO CapitalConor MacKay$19249.1% upsideOpen
2026-07-20H.C. WainwrightAndrew Fein$22070.8% upsideOpen
2026-07-15Wells Fargo$16125% upsideOpen
2026-06-16Mizuho SecuritiesGraig Suvannavejh$19249.1% upsideOpen
2026-05-13Truist Financial$18543.6% upsideOpen
2026-05-08Wells Fargo$16024.2% upsideOpen
2026-05-08GuggenheimVamil Divan$22675.5% upsideOpen
2026-04-16Guggenheim$23078.6% upsideOpen
2026-04-14RBC Capital$21667.7% upsideOpen
2026-04-10Raymond James$20055.3% upsideOpen
2026-04-08Mizuho Securities$20256.8% upsideOpen
2026-03-26H.C. Wainwright$24590.2% upsideOpen
2026-02-24Mizuho Securities$20458.4% upsideOpen
2026-02-20Morgan Stanley$16628.9% upsideOpen
2026-02-20Wells FargoTiago Fauth$20861.5% upsideOpen
2026-02-19Stifel Nicolaus$20559.2% upsideOpen
2026-02-19Mizuho SecuritiesGraig Suvannavejh$21163.8% upsideOpen
2026-01-27BarclaysEliana Merle$23179.3% upsideOpen
2026-01-22Roth Capital$21264.6% upsideOpen
2026-01-21RBC CapitalLeonid Timashev$20055.3% upsideOpen
2026-01-12Truist FinancialDanielle Brill$20559.2% upsideOpen
2026-01-08Morgan StanleyMaxwell Skor$15721.9% upsideOpen
2026-01-06UBS$21566.9% upsideOpen
2025-12-19Truist FinancialDanielle Brill$20256.8% upsideOpen
2025-12-18H.C. Wainwright$23078.6% upsideOpen
2025-12-18Cowen & Co.$24187.1% upsideOpen
2025-12-18Mizuho SecuritiesGraig Suvannavejh$21264.6% upsideOpen
2025-12-18Guggenheim$22171.6% upsideOpen
2025-12-18Wedbush$20357.6% upsideOpen
2025-12-18RBC CapitalLeonid Timashev$19551.4% upsideOpen
2025-12-18Wells Fargo$19551.4% upsideOpen
2025-12-18Wolfe ResearchAndy Chen$16729.7% upsideOpen
2025-12-16Wells FargoTiago Fauth$23481.7% upsideOpen
2025-12-16Cantor FitzgeraldOlivia Brayer$23078.6% upsideOpen
2025-12-10Jefferies$269108.9% upsideOpen
2025-12-04Redburn Partners$263104.2% upsideOpen
2025-12-01Mizuho SecuritiesGraig Suvannavejh$25698.8% upsideOpen
2025-10-31Goldman Sachs$22574.7% upsideOpen
2025-10-31RBC CapitalLeonid Timashev$21566.9% upsideOpen
2025-10-31UBSTrung Huynh$22373.1% upsideOpen
2025-10-31Wells Fargo$21768.5% upsideOpen
2025-10-29Mizuho SecuritiesGraig Suvannavejh$19652.2% upsideOpen

Insmed (INSM) FAQ

Insmed posts a target price of $190. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $190 for INSM means covering analysts, on average, see the stock 48.7% upside of $128.8 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for INSM's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Insmed's other metric pages and overview cover the third.

Judging Insmed against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $190 here, then scan peer and history charts to see if the gap is persistent.